NCT01388582

Brief Summary

The investigators propose a randomized clinical trial comparing the effect of 30 mcg ethinyl estradiol and LNG 150 combination oral contraceptive pills versus placebo, or LNG-IUS or Etonogestrel-releasing contraceptive implant (Implanon)on breast-milk intake and infant growth in exclusively breastfeeding mother-infant pairs. Mother-infant pairs will be randomly assigned either 30 microgram ethinyl estradiol combination oral contraceptive pills or identical placebo to start on post-partum day number 42 or Implanon implants or a LNG-IUS. All women will be offered nonhormonal contraceptives prior to randomization. The pairs will then be followed for four weeks. During this follow-up period, breast-milk intake will be quantified by administering deuterium oxide to exclusively breast-feeding mothers and measuring the enrichment of deuterium oxide in the saliva of their infants, otherwise known as the dose-to-mother method of Coward.17 Additionally, maternal and infant anthropometric measurements will be collected -- both as a value necessary to implement the breast-milk quantification method, as well as an outcome for analysis, and a daily diary will be kept by the women participating in the study that records infant feeds and diaper changes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2011

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 16, 2011

Completed
20 days until next milestone

First Posted

Study publicly available on registry

July 6, 2011

Completed
26 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2011

Completed
Last Updated

May 17, 2012

Status Verified

May 1, 2012

Enrollment Period

4 months

First QC Date

June 16, 2011

Last Update Submit

May 16, 2012

Conditions

Keywords

contraceptiveshormonalbreastfeedinginfant weight

Outcome Measures

Primary Outcomes (1)

  • Evaluation of infant weight, height and size of the tibial

    The study have the purpose to evaluate the infant weight, height and size of the tibial in infant who breastfeeding on demand exclusively and their mother were either users of a combined oral contraceptive, placebo, etonogestrel-releasing subdermal contraceptive implant or levonorgestrel-releasing intrauterine system. Additionally, pregnancy effectiveness and any adversse event will record in all groups of women.

    women and children will be evaluated at time frame from day 42 through day 64 post-partum

Study Arms (4)

Combined oral contraceptive

ACTIVE COMPARATOR

10 women will receive COC during breastfeeding

Drug: 30 mcg EE and 150 LNG oral contraceptive (Microvlar)Device: TCu380A intrauterine device

Levonorgestrel intrauterine system

ACTIVE COMPARATOR

10 women will receive a LNG-IUS during breastfeeding

Device: LNG-IUSDevice: TCu380A intrauterine device

Implanon

ACTIVE COMPARATOR

10 women will receive Implanon during breastfeeding

Device: ImplanonDevice: TCu380A intrauterine device

TCu380A intrauterine device

ACTIVE COMPARATOR

10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding

Device: TCu380A copper-intrauterine deviceDevice: TCu380A intrauterine device

Interventions

LNG-IUSDEVICE

10 women will receive the LNG-IUS during breastfeeding

Also known as: Mirena, Bayer, Brazil
Levonorgestrel intrauterine system
ImplanonDEVICE

60 mcg/day contraceptive implant

Also known as: Implanon, MSD, Brazil
Implanon

10 women will receive oral contraceptive during breastfeeding

Also known as: Microvlar (Bayer, Brazil)
Combined oral contraceptive

Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group

Also known as: Optima IUD (Injeflex, Brazil)
TCu380A intrauterine device

10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding

Also known as: Implanon, MSD, Os, The Netherland, Mirena, Bayer Oy, Tuku, Finland, TCu380A copper intrauterine device; Optima, Injeflex, Brazil, Microvlar oral contraceptive, Bayer, São Paulo, Brazil
Combined oral contraceptiveImplanonLevonorgestrel intrauterine systemTCu380A intrauterine device

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • women at the day 42th of post-partum fully breastfeeding-

You may not qualify if:

  • baby premature
  • diabetes
  • blood hypertension
  • not breastfeeding or partial breastfeeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Campinas

Campinas, São Paulo, 13083-888, Brazil

Location

Related Publications (1)

  • Bahamondes L, Bahamondes MV, Modesto W, Tilley IB, Magalhaes A, Pinto e Silva JL, Amaral E, Mishell DR Jr. Effect of hormonal contraceptives during breastfeeding on infant's milk ingestion and growth. Fertil Steril. 2013 Aug;100(2):445-50. doi: 10.1016/j.fertnstert.2013.03.039. Epub 2013 Apr 23.

MeSH Terms

Conditions

ThinnessBreast Feeding

Condition Hierarchy (Ancestors)

Body WeightSigns and SymptomsPathological Conditions, Signs and SymptomsFeeding BehaviorBehavior

Study Officials

  • Luis Bahamondes, MD

    University of Campinas

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD Medical Doctor

Study Record Dates

First Submitted

June 16, 2011

First Posted

July 6, 2011

Study Start

April 1, 2011

Primary Completion

August 1, 2011

Study Completion

August 1, 2011

Last Updated

May 17, 2012

Record last verified: 2012-05

Locations